T-Cell Receptor Alternate Reading Frame Protein, (TARP) and Uses Thereof
Description of Invention:
This invention relates to a tumor-associated protein, TARP, which is expressed in breast and prostate cancer cells. This antigen target might be a useful tool for the diagnosis and treatment of breast and prostate cancer. TARP has shown efficacy in vivo as a potential therapeutic for the treatment of cancer. TARP has been the subject of several publications, including: J. Biol. Chem. (2004 Jun 4) 279(23):24561-24568, Epub 2004 Mar 29 as doi:10.1074/jbc.M402492200; Cancer Res. (2004 Apr 1) 64(7):2610-2618; Endocrinology (2003 Aug) 144(8):3433-40; Cancer Res. (2001 Nov 15) 61(22):8122-8126; Proc. Natl. Acad. Sci. USA (2000 Aug 15) 97(17):9437-9442.
Inventors:
Ira Pastan (NCI) Magnus Essand (NCI) Byungkook Lee (NCI) George Vasmatzis (NCI) Ulrich Brinkman (NCI) Paul Duray (NCI) and Curt Wolfgang (NCI)
Patent Status:
DHHS Reference No. E-104-1999/2 Licensing Status: This technology is no longer available for licensing.
Portfolios: Cancer
Cancer -Diagnostics-In Vitro-DNA Based Cancer -Diagnostics-In Vivo-MAb Cancer -Therapeutics-Gene Therapy-Genes Cancer -Diagnostics Cancer -Therapeutics
For Additional Information Please Contact: Jasbir (Jesse) S. Kindra J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-5559
Email: kindraj@mail.nih.gov
Fax: (301) 402-0220
